Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
May 7, 2019 Off

Charles River Laboratories Announces First-Quarter 2019 Results

By BusinessWire

– First-Quarter Revenue of $604.6 Million – – First-Quarter GAAP Earnings per Share of $1.11 and Non-GAAP Earnings per Share…

May 7, 2019 Off

Repair Biotechnologies Raises $2.15M Seed Round to Develop Drugs for Age-Related Diseases

By BusinessWire

SYRACUSE, N.Y.–(BUSINESS WIRE)–Repair Biotechnologies, Inc. announced today $2.15 million in seed venture funding, to accelerate the preclinical development of its…

May 7, 2019 Off

Ra Pharmaceuticals Announces Positive gMG Phase 2 and Open-Label, Long-Term Extension Data at the 2019 AAN Annual Meeting

By BusinessWire

Open-label, long-term extension data show durability of zilucoplan treatment effect, with sustained improvements observed in primary and secondary endpoints at…

May 7, 2019 Off

FSD Pharma Announces Research Agreement with Solarvest to Develop Algae-based, Pharma-grade Cannabinoids

By BusinessWire

– Process Could Significantly Reduce Cannabinoid Production Time – TORONTO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/FSDDF?src=hash" target="_blank"gt;#FSDDFlt;/agt;–FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA:…

May 7, 2019 Off

Rocket Pharmaceuticals Announces Participation at the Bank of America Merrill Lynch 2019 Healthcare Conference

By BusinessWire

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform clinical-stage gene therapy company, today announces that Gaurav Shah,…

May 7, 2019 Off

Eagle Pharmaceuticals, Inc. Reports First Quarter 2019 Results

By BusinessWire

— Q1 2019 net income of $0.64 per basic and $0.62 per diluted share and adjusted non-GAAP net income of…

May 7, 2019 Off

Merck’s BELSOMRA® (suvorexant) C-IV Meets Primary Efficacy Endpoint in Phase 3 Trial for the Treatment of Insomnia in People with Mild-to-Moderate Alzheimer’s Disease Dementia

By BusinessWire

First Randomized Controlled Polysomnography Trial of Insomnia Medication in Alzheimer’s Disease Dementia Population Data to be Filed with FDA for…

May 7, 2019 Off

Eagle Pharmaceuticals Announces Positive Results of a Study Conducted in Partnership with the U.S. Military to Evaluate Neuroprotective Effects of RYANODEX for the Treatment of Nerve Agent Exposure

By BusinessWire

— Statistically significant lower incidence of brain damage compared to control group, demonstrating neuroprotective properties of RYANODEX in treating nerve…

May 7, 2019 Off

Algiax Pharmaceuticals Announces New Executive Team and Clinical Trial Plan for Lead Candidate AP-325

By BusinessWire

Algiax Pharmaceuticals Appoints Dr. Ingo Lehrke and Dr. Guido Koopmans as CEO and CSO. A Proof-of-Concept Study for Neuropathic Pain…

May 7, 2019 Off

Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV

By BusinessWire

Company to Develop Gene Editing Therapies to Permanently Reduce Risk of Coronary Artery Disease in Adults Announces Key Licensing Agreements…

Posts pagination

Previous 1 … 3,220 3,221 3,222 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine